MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis by Murugaiyan, Gopal et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
MicroRNA-21 promotes Th17 differentiation and mediates experimental
autoimmune encephalomyelitis
Murugaiyan, Gopal; da Cunha, Andre Pires; Ajay, Amrendra K; Joller, Nicole; Garo, Lucien P;
Kumaradevan, Sowmiya; Yosef, Nir; Vaidya, Vishal S; Weiner, Howard L
Abstract: Accumulation of IL-17–producing Th17 cells is associated with the development of multiple
autoimmune diseases; however, the contribution of microRNA (miRNA) pathways to the intrinsic control
of Th17 development remains unclear. Here, we demonstrated that miR-21 expression is elevated in Th17
cells and that mice lacking miR-21 have a defect in Th17 differentiation and are resistant to experimental
autoimmune encephalomyelitis (EAE). Furthermore, we determined that miR-21 promotes Th17 differ-
entiation by targeting and depleting SMAD-7, a negative regulator of TGF-￿ signaling. Moreover, the
decreases in Th17 differentiation in miR-21–deficient T cells were associated with defects in SMAD-2/3
activation and IL-2 suppression. Finally, we found that treatment of WT mice with an anti–miR-21
oligonucleotide reduced the clinical severity of EAE, which was associated with a decrease in Th17 cells.
Thus, we have characterized a T cell–intrinsic miRNA pathway that enhances TGF-￿ signaling, limits the
autocrine inhibitory effects of IL-2, and thereby promotes Th17 differentiation and autoimmunity.
DOI: 10.1172/JCI74347
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-118363
Published Version
Originally published at:
Murugaiyan, Gopal; da Cunha, Andre Pires; Ajay, Amrendra K; Joller, Nicole; Garo, Lucien P; Kuma-
radevan, Sowmiya; Yosef, Nir; Vaidya, Vishal S; Weiner, Howard L (2015). MicroRNA-21 promotes Th17
differentiation and mediates experimental autoimmune encephalomyelitis. Journal of Clinical Investiga-
tion, 125(3):1069-1080. DOI: 10.1172/JCI74347
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1jci.org
Introduction
IL-17–producing Th17 cells contribute to protection against micro-
bial pathogens but also play a critical role in the development of 
autoimmunity (1), including multiple sclerosis (MS) and its ani-
mal model experimental autoimmune encephalomyelitis (EAE) 
(2–5). Multiple cytokines including TGF-β, IL-6, IL-1β, and IL-21 
have been shown to induce the differentiation of naive T cells 
toward the Th17 phenotype (6–11). The differentiation of Th17 
cells requires expression of the transcription factor ROR-γt (12). 
The induction of ROR-γt is dependent on STAT-3, which is prefer-
entially activated by IL-6. In addition, other transcription factors 
including ROR-α, IRF-4, BATF, and HIF-1α are also involved in the 
control of Th17 lineage commitment (13–16).
Among the cytokines, TGF-β critically promotes Th17-medi-
ated immune responses. Altered TGF-β and TGF-β receptor 
(TGF-βR) signaling have been implicated in Th17-mediated 
autoimmune pathogenesis (6, 7). For example, mice expressing 
dominant-negative TGF-βRII confer resistance to EAE through 
a reduction in Th17 cells (17). TGF-β signals are transduced 
through activation of the SMAD proteins SMAD-2 and SMAD-3 
(18), and enhanced generation of Th17 cells is associated with 
increased TGF-β–induced SMAD-2/3 activation (19–21). In 
addition, TGF-β signaling has been shown to downregulate IL-2 
expression and abrogate IL-2–mediated suppression of Th17 dif-
ferentiation (20–23). However, the role that microRNAs (miR-
NAs) play in the activation of TGF-βR signaling in driving Th17 
cell development and, consequently, Th17-mediated autoimmu-
nity remains unknown.
miRNAs are a class of small, noncoding RNAs that impart 
posttranscriptional gene regulation through several mechanisms 
including translational repression and mRNA degradation (24). 
They are important in many physiological processes such as car-
cinogenesis and immune system modulation. Aberrant expres-
sion of miRNAs has been linked to a variety of human pathologies 
including MS and other inflammatory diseases (25, 26).
Here, we report that miR-21 expression was specifically ele-
vated in Th17 cells and that miR-21–deficient (Mir21–/–) mice showed 
a defect in Th17 differentiation and strong resistance to EAE. 
miR-21 promoted Th17 differentiation by targeting SMAD-7, a nega-
tive regulator of TGF-β signaling. The defects in Th17 differentiation in 
Mir21–/– T cells were associated with defects in SMAD-2/3 activation 
and IL-2 suppression. Anti–miR-21 treatment dramatically reduced 
the clinical severity of EAE and decreased Th17 cell numbers. 
Thus, our results characterize a previously unknown T cell–intrinsic 
miRNA pathway that promotes Th17 differentiation and autoim-
munity and identifies miR-21 as a potential therapeutic target in the 
amelioration of MS and other Th17-mediated autoimmune diseases.
Results
miR-21 promotes Th17 differentiation. CD4+ T cells play a major 
role in autoimmune disease. Increased expression of miR-21 
has been observed in human autoimmune conditions including 
MS, systemic lupus erythematosus (SLE), and psoriasis (27–30). 
However, the role of miR-21 and its intrinsic requirement in Th 
cell differentiation and autoimmunity remains unclear. To inves-
tigate the expression of miR-21 in Th cell subsets, we activated 
naive CD4+CD62LhiCD44lo T cells under polarizing conditions in 
vitro and obtained Th1, Th2, Th17, and Treg cells with selective 
expression of Ifng, Il4, Il17, and Foxp3, respectively (Supplemen-
tal Figure 1A; supplemental material available online with this 
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compared with that in WT T cells (Figure 2, A 
and B). Consistent with this, Mir21–/– T cells dif-
ferentiated under Th17-polarizing conditions 
expressed lower levels of Th17-associated tran-
scription factors (Rorgt, Rora, Irf4, Hif1a, and 
Batf), cytokines (Il17f, Il21, Il22, and Gmcsf), 
and cell-surface receptors (Il23r and Ccr6) 
(Figure 2, C–E). In contrast, in vitro differenti-
ation of Th1 and Th2 effector cells was largely 
independent of miR-21 (Supplemental Figure 
2A). Phenotypical analysis of iTregs revealed 
a dispensable role of miR-21 in iTreg cell dif-
ferentiation, as reflected by unaltered FOXP3 
expression (Supplemental Figure 2B). More-
over, we detected no developmental defect in 
the generation of CD25+FOXP3+ natural Tregs 
(nTregs) in the absence of miR-21 (Supplemen-
tal Figure 2C). To investigate whether deletion 
of miR-21 affected the homeostasis of T cells, 
B cells, and DC populations, we analyzed 6- to 
8-week-old naive Mir21–/– mice and WT control 
mice. In the thymus, the frequencies of CD4+ 
and CD8+ single-positive as well as CD4+CD8+ 
double-positive T cells were unaltered (Supplemental Figure 3A). In 
addition, we found comparable sizes of lymphoid and myeloid cell 
subsets in the spleen (Supplemental Figure 3, A–D). Furthermore, 
the size and total cellularity of spleens and inguinal lymph nodes 
(LNs) were comparable between WT and Mir21–/– mice (Supple-
mental Figure 3, E and F). Collectively, these results provide evi-
dence that miR-21 is not required to effectively induce Th1, Th2, or 
Tregs and suggest a selective role for miR-21 in Th17 cells.
miR-21 regulates EAE development. These observations led us 
to explore the potential role of miR-21 in Th17-mediated inflam-
matory immune pathogenesis in vivo. To investigate the role of 
miR-21 in EAE development, we first analyzed the expression of 
miR-21 in mice during the course of EAE. Since CD4+ T cells are 
the key mediators of EAE, we asked whether CD4+ T cells express 
miR-21 during EAE. We analyzed miR-21 expression in CD4+T 
cells from C57BL/6 mice immunized against EAE with MOG35–55 
peptide emulsified in CFA and found that miR-21 expression was 
markedly increased in CD4+ T cells isolated from the spleen and 
CNS of EAE mice compared with that in naive mice (Figure 3A). 
The potential role of miR-21 in EAE pathogenesis was then tested 
using Mir21–/– mice. In 4 independent experiments, Mir21–/– mice 
were resistant to EAE induction (2 of 38 mice developed EAE), 
whereas WT mice developed severe EAE (35 of 38 mice developed 
EAE) (Figure 3B). The absence of paralytic symptoms in Mir21–/– 
mice was associated with a marked reduction in inflammation and 
demyelination (Figure 3, C and D). Although we found that EAE 
was associated with demyelination and infiltration of CD4+ T cells 
and CD11c+ cells from the peripheral lymphoid organs to the CNS 
in both WT and Mir21–/– mice, the total number of CD4+ T cells and 
CD11c+ cells was markedly lower in the CNS of Mir21–/– mice at the 
peak of disease (Figure 3E).
miR-21 has been reported to target various tumor-suppressor 
genes such as Btg2, Pdcd4, Pten, and sprouty, which are known to 
regulate cell death and proliferation (32–39). We therefore tested 
article; doi:10.1172/JCI74347DS1). We found large amounts of 
miR-21 in Th17 cells and relatively small amounts in Th1, Th2, 
and inducible Tregs (iTregs) (Figure 1, A and B). We used 2 differ-
ent endogenous controls (small nucleolar RNA135 [snoRNA135] 
and U6 small nuclear RNA [snRNA]) to analyze miR-21 expres-
sion in T cells and found similar results (Figure 1, A and B). We 
then investigated whether T cell antigen receptor (TCR) stimu-
lation was required for TGF-β and IL-6–induced miR-21 upreg-
ulation in T cells and found that stimulation via the TCR and 
CD28 led to a small increase in miR-21 levels compared with 
that observed in unstimulated cells. The addition of TGF-β and 
IL-6 further increased miR-21 expression (Supplemental Figure 
1B). Moreover, miR-21 was specifically upregulated in T cells that 
were stimulated under Th17 conditions (Figure 1, A and B).
Th17 cells have been reported to express chemokine receptor 
CCR6 (31). To test whether IL-17 expression in CCR6+ cells cor-
related with miR-21 expression, we sorted CCR6+ and CCR6– T cells 
from Th17 cultures and found that CCR6+ cells had higher miR-21 
expression than  did CCR6– cells (Figure 1C), along with increased 
Il17 expression (Supplemental Figure 1C). Although in vitro polar-
ization recapitulates the phenotypes of different Th lineages, in 
vitro and in vivo polarized cells may not be identical. Therefore, 
we assessed miR-21 expression levels in freshly isolated T cells. To 
this end, CD4+ T cells were sorted ex vivo based on IL-17 expres-
sion as assessed using an IL-17 secretion assay. Consistent with the 
data obtained from in vitro polarized cells, IL-17–secreting cells 
expressed higher levels of miR-21 when compared with the levels 
seen in IL-17–CD4+ T cells (Figure 1D), along with the enrichment 
of IL-17 expression (Supplemental Figure 1D). Taken together, these 
data indicate that miR-21 is differentially expressed in Th17 cells.
To directly assess whether miR-21 regulated the differentiation 
of Th17 cells, we performed an in vitro T cell differentiation assay. 
When naive CD4+ T cells were activated under Th17-polarizing con-
ditions, IL-17 production in Mir21–/– T cells was significantly reduced 
Figure 1. miR-21 is specifically induced in Th17 cells. (A and B) Naive CD4+CD62LhiCD44lo T cells 
were activated with plate-bound anti-CD3 (2 μg/ml) and anti-CD28 (2 μg/ml) in the presence of 
Th1-, Th2-, Th17-, and Treg-polarizing conditions in vitro. Twenty-four hours later, miR-21 expres-
sion was analyzed by quantitative RT-PCR (qRT-PCR) using the snRNAs snoRNA135 and U6 snRNA 
as endogenous controls. (C) qRT-PCR analysis of miR-21 expression in flow cytometric–sorted 
CCR6+CD4+ and CCR6–CD4+ T cells from in vitro Th17 cultures. (D) CD4+ T cells from C57BL/6 mice 
were sorted into IL-17A+ and IL-17A– cell populations and analyzed for expression of miR-21 by qRT-
PCR. Data are representative of 3 independent experiments. Error bars represent the mean ± SEM. 
**P < 0.01 and ***P < 0.001 by unpaired Student’s t test. Med, medium.
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abnormality in Mir21–/– T cells is not a major contributor to the 
striking EAE resistance we observed in these mice.
We further investigated whether the EAE resistance in Mir21–/– 
was associated with a defect in cytokine production from T cells. 
At peak disease, CNS-infiltrating CD4+ T cells from Mir21–/– mice 
produced less IL-17, whereas IFN-γ levels were unaffected (Figure 
3F). In line with a reduction in the frequency of IL-17–produc-
ing cells in the CNS, mRNA expression of other Th17-associated 
genes in T cells from Mir21–/– mice was also reduced in comparison 
with expression in T cells from WT mice (Figure 3G). Consistent 
with these RNA data, analysis of CNS-infiltrating Th17 cells for 
intracellular cytokines revealed a significant defect in expression 
of the Th17-related cytokines IL-17A and IL-17F in Mir21–/– mice. 
However, the protein levels of IL-21 and IL-22 were not altered 
between WT and Mir21–/– mice (Supplemental Figure 5). In addi-
tion, we found that Mir21–/– mice had substantially reduced per-
centages (Figure 3H) and absolute numbers (Supplemental Figure 
6) of Th17 cells in the CNS compared with those detected in WT 
mice at the onset and peak stages of EAE. Furthermore, we found 
that Mir21–/– mice had substantially diminished percentages of 
Th17 cells in the periphery compared with those detected in WT 
mice at the onset and peak stages of EAE (Supplemental Figure 7). 
whether miR-21 affects the cell death and proliferation of CD4+ 
T cells by targeting these tumor suppressors. Although we found 
that in vitro–stimulated Mir21–/– T cells expressed higher levels of 
Pten than did their WT counterparts (Supplemental Figure 4A), 
no significant differences in the expression of these target genes 
were observed between WT and Mir21–/– T cells in vivo (Supple-
mental Figure 4B). Consistent with the increased expression of 
Pten in vitro, we found that naive Mir21–/– T cells stimulated in 
vitro exhibited a proliferative defect (Supplemental Figure 4C). 
However, we found no significant differences in any of the exam-
ined proliferative parameters between MOG-immunized WT and 
Mir21–/– T cells in response to MOG antigen (Supplemental Fig-
ure 4D). In addition, no difference in the frequencies of apoptotic 
T cells between WT and Mir21–/– mice was observed (Supplemen-
tal Figure 4, E and F) either in vitro or in vivo. Consistent with 
these findings, the total spleen cellularity, frequency of activated 
(CD44hi) CD4+ T cells, and percentage of MOG-tetramer+ T cells 
were similar between WT and Mir21–/– mice during EAE induc-
tion (Supplemental Figure 4, G–I). Together, these results estab-
lish the presence of MOG-specific T cells in Mir21–/– mice and 
demonstrate the ability of these T cells to expand in response to 
MOG peptide, suggesting that a general proliferative or apoptotic 
Figure 2. miR-21 promotes Th17 differentiation. (A) Il17a expression in WT 
and Mir21–/– T cells cultured under Th17 conditions determined by qRT-PCR. 
(B) WT and Mir21–/–-derived naive CD4+ T cells cultured under Th17 conditions 
were restimulated with PMA plus ionomycin on day 5 and stained for IL-17 
and IFN-γ. Numbers represent the frequency of CD4+ T cells. (C–E) Naive CD4+ 
T cells from WT and Mir21–/– mice were differentiated into Th17 cells. mRNA 
expression levels of Th17-related cytokines (Il17a, Il17f, Il21, Il22, and Gmcsf), 
transcription factors (Rorgt, Rora, Irf4, Hif1a, and Batf), and surface receptors 
(Il23r and Ccr6) were analyzed by qRT-PCR. Data are representative of 3 inde-
pendent experiments. Error bars represent the mean ± SEM. **P < 0.01, and 
***P < 0.001 by unpaired Student’s t test.
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levels of costimulatory molecules (Supplemental Figure 8A) and 
Th17-polarizing cytokines Il6, Il23, Il1b, and Tnfa after LPS stim-
ulation (Supplemental Figure 8B). In addition, coculture of naive 
CD4+ T cells and DCs indicated that Mir21–/– DCs were able to sup-
port Th17 development normally. However, Th17 development 
from Mir21–/– naive CD4+ T cells was markedly impaired, regard-
less of the origin of the cocultured DCs (Supplemental Figure 8C). 
IL-17–producing innate lymphoid cells have been shown to play a 
pathological role in certain autoimmune diseases (41). However, 
we did not find any difference between WT and Mir21–/– mice in 
the frequency of innate lymphoid cells or the expression of IL-17 
in these cells (Supplemental Figure 9). Collectively, these data 
Together, these data demonstrate that miR-21 positively regulates 
Th17 differentiation both in vivo and in vitro.
DCs play an important role in the development of EAE and 
produce inflammatory cytokines that are required for Th17 dif-
ferentiation and function in vivo (8). Among the DC-secreted 
cytokines, IL-23 is crucial for the functional maturation of Th17 
cells. In fact, IL-23R–deficient mice were shown to be resistant to 
EAE, owing to a specific defect in Th17 cells (40). To investigate 
the possibility that impaired Th17 differentiation in Mir21–/– mice 
was caused by a defect in DCs, we evaluated inflammatory cytok-
ine expression and costimulatory molecule expression in DCs. We 
found that DCs from both WT and Mir21–/– mice expressed normal 
Figure 3. miR-21–deficient mice are resistant to EAE. (A) Mir21 mRNA was determined by RT-PCR analysis in CD4+ T cells from the spleen and then the 
CNS of naive and EAE mice at peak disease stage. (B) Clinical scores of WT and Mir21–/– mice (n = 8) after immunization with MOG33–55 in CFA. (C and D) 
Histopathological analysis of spinal cord sections from WT and Mir21–/– mice (n = 3) 20 days after immunization. Original magnification, ×20 (C) and ×40 
(D). (E) Mononuclear cell numbers pooled from the CNS of WT and Mir21–/– mice (n = 3) 20 days after immunization. (F) Intracellular staining of IFN-γ and 
IL-17 in CNS-derived CD4+ T cells from WT and Mir21–/– mice with EAE. Numbers indicate the percentage of CD4+ cells. (G) mRNA expression of Th17-related 
cytokines, transcription factors, and surface receptors from CD4+ T cells within the CNS as determined by RT-PCR. (H) FACS analysis of frequencies of 
IL-17–producing CD4+ T cells from the CNS of the indicated groups. (I) WT and Mir21–/– mice (n = 5) were injected i.v. with WT CD4+ T cells 5 days before EAE 
induction. (J) FACS analysis of frequencies of IFN-γ– and IL-17–producing CD4+ T cells from the CNS of the indicated groups. (K) Disease course of adoptive 
EAE in WT recipients, reconstituted with Th17-polarized cells from WT or Mir21–/– mice (n = 5). (L) FACS analysis of frequencies of GM-CSF–, IL-17–, and 
IFN-γ–producing CD4+ T cells from the CNS of the indicated groups. Data are representative of 3 independent experiments. Error bars represent the mean ± 
SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by unpaired Student’s t test.
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find any defect in TGF-β or TGF-βR expression in Mir21–/– CD4+ T 
cells (Supplemental Figure 12), stimulation of Mir21–/– CD4+ T cells 
with TGF-β resulted in reduced phosphorylation of both SMAD-2 
and SMAD-3 when compared with that in WT CD4+ T cells (Fig-
ure 4A). Strikingly, stimulation of Mir21–/– CD4+ T cells with TGF-β 
resulted in higher SMAD-7 expression (Figure 4B). Contrary to the 
function of SMAD-2/3, TGF-β–induced SMAD-7 participates in a 
negative feedback loop to control excessive TGF-β signaling.
We thus applied the Web-based target prediction software 
program TargetScan (www.targetscan.org) to identify potential 
miR-21 targets and found miR-21 to be a potential upstream regu-
lator of SMAD-7 (Figure 4C). In addition, recent data from other 
disease models suggest that miR-21 is an upstream regulator of 
SMAD-7 (47, 48). To determine whether SMAD-7 is a target of 
miR-21 in Th17 differentiation, we performed luciferase assays 
using the WT and mutant Smad7 3′ UTR. We found that miR-21 
inhibited the luciferase activity of a reporter containing the WT 
Smad7 3′ UTR, but not that of a reporter with a mutated 3′ UTR 
unable to bind to miR-21 (Figure 4, D and E). The effect of miR-
21 on SMAD-7 expression was then tested by using a chemically 
modified locked nucleic acid (LNA) inhibitor. We found that 
inhibition of miR-21 led to an increase in SMAD-7 expression 
in CD4+ T cells treated with TGF-β (Figure 4F). Consistent with 
the increased levels of SMAD-7, inhibition of miR-21 also led to 
decreased phosphorylation of SMAD-2 and SMAD-3 in CD4+ T 
cells (Figure 4F). On the other hand, miR-21 overexpression sub-
stantially decreased the levels of SMAD-7 while increasing the 
expression of SMAD-2 and SMAD-3 (Figure 4G). In addition to 
the SMAD-dependent signaling pathway, TGF-β is also known to 
signal via a SMAD-independent pathway (18). However, we did 
not find any difference between WT and Mir21–/– T cells in the 
activation levels of molecules associated with non-SMAD TGF-β 
signaling pathways including p38 MAPK, ERK-1/2, and stress- 
activated protein kinase (SAPK)/Jun amino-terminal kinase 
(JNK) (Supplemental Figure 13). Taken together, our results 
suggest that by targeting SMAD-7, miR-21 promotes SMAD- 
mediated TGF-β signaling and that its deletion results in reduced 
sensitivity to the effects of TGF-β in T cells.
Next, we tested the functional role of miR-21 in regulating the 
effects of TGF-β on Th17 differentiation and the role of SMAD-7 
in regulating these effects. CD4+ T cells were transfected with 
lentiviral shRNA against SMAD-7 and cultured under Th17 
conditions. Knockdown of SMAD-7 in CD4+T cells resulted in 
increased production of IL-17 and other Th17-related cytokines 
with concomitant downregulation of IL-2 (Figure 4, H–J). Consis-
tent with the downregulation of IL-2, SMAD-7 inhibition resulted 
in enhanced SMAD-2 and SMAD-3 phosphorylation (Figure 4K). 
Similarly, we found an increase in IL-17 levels when SMAD-7 was 
knocked down in CD4+ T cells using SMAD-7–conditional–KO 
mice (Figure 4L). To determine whether reducing SMAD-7 lev-
els in Mir21–/– mice would restore Th17 differentiation in Mir21–
/– CD4+ T cells, we blocked SMAD-7 expression using lentiviral 
shRNAs and found that blocking SMAD-7 activity restored IL-17 
levels in Mir21–/– Th17 cells, which was associated with a reduc-
tion in IL-2 levels (Figure 4M). It has been demonstrated that 
TGF-β inhibits IL-2 production of T cells in a SMAD-3–depen-
dent manner (22, 47). In addition, a SMAD-binding element 
suggest that Mir21–/– CD4+ T cells have an intrinsic defect in their 
ability to differentiate into Th17 cells, resulting in amelioration of 
EAE in Mir21–/– animals.
To establish that the resistance to EAE in Mir21–/– mice resulted 
from a T cell–intrinsic defect, we transferred WT CD4+ T cells into 
WT or Mir21–/– mice before MOG immunization. Both WT and 
Mir21–/– mice receiving CD4+ T cells from WT mice developed 
EAE accompanied by CNS-infiltrating IL-17–producing CD4+ 
T cells, suggesting that miR-21–sufficient T cells from WT mice can 
overcome the EAE resistance in Mir21–/– mice (Figure 3, I and J). 
We further examined whether the EAE resistance of Mir21–/– mice 
might be due to their nonfunctional T cells. To test this hypothesis, 
MOG-specific Th17 and Th1 cells of Mir21–/– and WT origin were 
injected into syngeneic WT recipients, and the animals were mon-
itored for signs of EAE. While the recipients of Th17 cells from WT 
mice developed severe EAE, Th17 cells from Mir21–/– mice were 
not able to induce disease (Figure 3K). Interestingly, we found that 
injection of MOG-specific WT Th1 cells resulted in severe EAE, 
whereas, transfer of MOG-specific Mir21–/– Th1 cells did not elicit 
any signs of EAE (Supplemental Figure 10). GM-CSF is the main 
effector cytokine in both Th1 and Th17 cell–driven EAE (42–44). 
In fact, Th1 cells that lack the ability to produce GM-CSF do not 
transfer EAE (42). We therefore assessed GM-CSF expression in 
Th1 and Th17 cells infiltrating the brains of WT and Mir21–/– mice 
with EAE. Interestingly, CNS-infiltrating Th1 and Th17 cells from 
Mir21–/– mice showed a dramatic drop in GM-CSF expression, sug-
gesting that miR-21 is critical for the encephalitogenic function of 
T cells in vivo (Figure 3L). It has been shown that the recruitment 
of myeloid cells is associated with pathogenic Th17 responses 
and GM-CSF secretion (45). Consistent with our observation of 
impaired IL-17 and GM-CSF secretion by CNS-infiltrating Mir21–/– 
Th17 cells, we observed a significant reduction in the number of 
CNS-infiltrating DCs and macrophages in Mir21–/– mice (Figure 
3E). It has also been shown that Th17 cells initially access the CNS 
and create a microenvironment conducive to the subsequent entry 
of Th1 cells (31). The defective Th17 differentiation, coupled with a 
reduction of GM-CSF secretion by both Th1 and Th17 cells, could 
explain the highly resistant EAE phenotype observed in Mir21–/– 
mice. Together, these observations demonstrate that EAE resis-
tance in Mir21–/– mice is caused by T cell–intrinsic defects.
miR-21 promotes Th17 differentiation through SMAD-7 inhibi-
tion. We then investigated the mechanism by which miR-21 reg-
ulates Th17 development. It is possible that miR-21 could control 
Th17 development by regulating IL-6 and TGF-β signaling. A crit-
ical mechanism of Th17 differentiation is IL-6–induced STAT-3 
activation (46). However, we did not find any difference in phos-
phorylated STAT-3 (p–STAT-3) levels between WT and Mir21–/– 
CD4+ T cells stimulated with IL-6 (Supplemental Figure 11A). In 
addition, there was no difference in IL-6 receptor (IL-6R) expres-
sion between the 2 genotypes, suggesting that Mir21–/– does not 
play a role in the modulation of signaling events downstream of the 
IL-6R (Supplemental Figure 11B). TGF-β initiates its cellular func-
tion by binding to TGF-βRII, which then phosphorylates TGF-βRI. 
TGF-βRI propagates the signal by inducing SMAD-2 and SMAD-3 
phosphorylation, which subsequently leads to nuclear transloca-
tion, SMAD-2 and SMAD-3 DNA binding, and the transcriptional 
activation of TGF-β–responsive genes (18). Although we did not 
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Figure 4. miR-21 promotes Th17 differentiation by targeting SMAD-7. (A and B) Representative immunoblots of phosphorylated and total SMAD-
2/3/7 proteins in CD4+ T cells from WT and Mir21–/– mice stimulated with TGF-β (2 ng/ml) for the indicated times. (C) miR-21 aligned with the highly 
conserved 3′ UTR of Smad7 mRNA. (D and E) Luciferase activity of a reporter carrying a mutant or WT Smad7 3′ UTR cotransfected into HEK-293 T 
cells with miR-21 or with its control. (F) Western blot analysis of SMAD-7, p–SMAD-2, and p–SMAD-3 in CD4+ T cells from WT mice treated with miR-21 
inhibitors or with its control. (G) Western blot analysis of SMAD-7, p–SMAD-2, and p–SMAD-3 in CD4+ T cells from WT mice treated with miR-21 precur-
sors or with its control. (H and I) SMAD-7 knockdown increased IL-17 and expression of other Th17-related cytokines in CD4+ T cells. Numbers represent 
the frequency of CD4+ cells. (J) ELISA of IL-2 in Th17 cells transduced with control or SMAD-7–specific shRNA. (K) SMAD-7 knockdown increased TGF-β–
induced SMAD-2/3 phosphorylation, while downregulating SMAD-7 levels. (L) Il17 expression in WT and Smad7–/– T cells cultured under Th17 condi-
tions. (M) SMAD-7 knockdown increased IL-17, while downregulating IL-2 in Mir21–/– Th17 cells. (N) ELISA of IL-2 in Th17 cells from WT and Mir21–/– mice. 
(O) Neutralization of IL-2 restored IL-17 levels in Mir21–/– Th17 cells. Data are representative of 2 to 3 independent experiments. Error bars represent the 
mean ± SEM. **P < 0.01 and ***P < 0.001 by unpaired Student’s t test.
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(SBE) is located upstream of the Il2 promoter, which is important 
for SMAD-mediated transcriptional suppression of IL-2 (49, 50). 
Furthermore, IL-2 has been shown to inhibit Th17 differentia-
tion both in vitro and in vivo (23, 51, 52). In order to elucidate the 
connection between impaired TGF-β–mediated SMAD signal-
ing and reduced Th17 responses in the absence of miR-21, we 
investigated IL-2 expression. 
Substantially elevated levels 
of IL-2 were observed in Th17 
cells from Mir21–/– T cells com-
pared with the levels detected 
in Th17 cells from WT T cells, 
which correlated with less 
production of IL-17 by Mir21–/– 
T cells (Figure 4N). To deter-
mine whether the increased 
production of IL-2 in Mir21–/– 
mice inhibited the generation 
of Th17 cells, we blocked IL-2 
activity in Th17 cultures using 
a combination of neutraliz-
ing anti–IL-2 and blocking 
anti–CD25 antibodies and 
found that blocking IL-2 activ-
ity restored IL-17 levels in 
Mir21–/–Th17 cells (Figure 4O). 
Together, these observations 
demonstrate that miR-21 lim-
its the production of IL-2 to 
promote Th17 differentiation. 
Furthermore, enhanced IL-2 
levels can offset the effect of 
TGF-β in Mir21–/– T cells and 
might explain the normal dif-
ferentiation of Tregs observed 
in these mice.
Silencing miR-21 amelio-
rates the clinical severity of EAE. 
The effect of miR-21 on IL-17 
expression was then tested 
using the miRNA inhibitor 
LNA–anti–miR-21. We found 
that silencing miR-21 in vitro 
led to decreased levels of miR-
21 and Il17 transcripts in T cells 
cultured under Th17-polarizing 
conditions (Figure 5, A and B). 
Furthermore, miR-21 silenc-
ing significantly decreased 
the expression of other cytok-
ines that are related to the 
Th17 phenotype (Figure 5C). 
We next investigated whether 
silencing miR-21 could inhibit 
the encephalitogenicity of 
Th17 cells in vivo. For this, we 
stimulated MOG-specific 2D2 
T cells under Th17-polarizing conditions in the presence of con-
trol or anti–miR-21 inhibitors and transferred the resulting T cells 
into syngeneic WT mice. Transplanted mice were injected with 
pertussis toxin (PT) on the day of T cell transfer and 48 hours later 
and monitored for the development of EAE. We found that mice 
that received Th17 cells differentiated in the presence of control 
Figure 5. Silencing miR-21 ameliorates the clinical severity of EAE. (A) qRT-PCR analysis of miR-21 in naive CD4+  
T cells cultured for 24 hours under Th0 conditions and transfected by nucleofection with the miR inhibitor LNA–
anti–miR-21 or scrambled control antisense oligonucleotide (LNA control), followed by Th17 differentiation for 
another 24 hours. (B) qRT-PCR and flow cytometric analysis of IL-17 in naive CD4+ T cells cultured for 24 hours in 
Th0 conditions and transfected by nucleofection with the miRNA inhibitor LNA–anti–miR-21 or scrambled control 
antisense oligonucleotide (LNA control), followed by Th17 differentiation for another 4 days. Numbers represent 
the frequencies of CD4+ T cells. (C) qRT-PCR analysis of Th17-related cytokines in Th17 cells polarized in the pres-
ence of control and anti–miR-21 inhibitors. (D) Disease course of adoptive EAE in WT recipients (n = 6), reconsti-
tuted with Th17 cells polarized in the presence of control and miR-21 inhibitors. (E) Silencing miR-21 ameliorated 
the clinical severity of EAE. Clinical EAE scores for WT mice (n = 6) treated with anti–miR-21 or scrambled control 
on days 5, 7, 9, 11, and 13 after immunization. (F) Splenocytes obtained from anti–miR-21 and scrambled control–
treated mice were restimulated with MOG35–55 (20 μg/ml) for 72 hours. Cell-free supernatants were assayed for IL-17 
by ELISA. (G) qRT-PCR analysis of Il17 in CNS-derived CD4+ T cells isolated from mice treated with or without anti–
miR-21. Results are representative of 2 independent experiments. Error bars represent the mean ± SEM. **P < 0.01 
and ***P < 0.001 by unpaired Student’s t test.
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TGF-β signaling through SMAD-dependent and SMAD-inde-
pendent pathways plays a role in Treg differentiation and function 
(56–61). Although TGF-β signaling through the SMAD-2/3 pathway 
has been demonstrated to partially regulate iTreg differentiation, it 
has also been shown that a combination of SMAD-2 and SMAD-3 
deficiency does not alter FOXP3 expression or the suppressive activ-
ity of iTregs in vivo (58). In fact, the development, homeostasis, and 
function of Tregs remained intact in SMAD-2 and SMAD-3 double–
deficient mice, suggesting a role for a SMAD-independent pathway 
in Treg differentiation and function (60). Among the SMAD-inde-
pendent TGF-β signaling pathways, p38 MAPK signaling has been 
shown to be required for the conversion of naive CD4+T cells into 
iTregs (61). Furthermore, IL-2 has been shown to stabilize TGF-β–
induced FOXP3 expression and compensate for the loss of defective 
SMAD-dependent TGF-β signaling in iTreg differentiation (21). Our 
observation of enhanced IL-2 levels and the unaltered SMAD-inde-
pendent TGF-β signaling pathway in Mir21–/– T cells seems to be 
able to offset the effect of TGF-β in these cells and might explain the 
normal differentiation of Tregs observed in Mir21–/– mice.
IL-2 has been shown to negatively regulate Th17 differentia-
tion both in vitro and in vivo (23, 49, 52, 62). For example, the 
uptake of extracellular IL-2 by Tregs promotes Th17 differentia-
tion (52). In addition to Tregs, the consumption of IL-2 by effector 
Th cells may limit the availability of IL-2 in the cellular microen-
vironment and prevent the paracrine effect of IL-2 on Th17 differ-
entiation. In fact, IL-2 has been shown to promote clonal expan-
sion and effector development of T cells in vivo and has been the 
growth-supporting cytokine in classical T cell clone–transferred 
EAE studies (63–65). Within Th17 cells, downregulation of IL-2 
expression by TGF-β occurs by a SMAD-mediated inhibition of 
gene transcription (20–23). We found that during Th17 differ-
entiation, miR-21 plays a significant role in the downregulation 
of IL-2 expression and that the antibody against IL-2 abrogated 
the observed defect in Th17 differentiation induced by Mir21–/– 
T cells. Therefore, our results suggest that miR-21 promotes the 
SMAD-mediated transcriptional downregulation of IL-2, acting 
as a positive regulator of Th17 differentiation. In the absence 
of miR-21, SMAD-7 levels are elevated, which in turn results in 
impaired TGF-β signaling, increased IL-2 expression, and the 
observed inhibition of Th17 differentiation (Figure 6). Thus, in 
addition to the T cell–extrinsic mechanism of IL-2 modulation, 
our results identify a T cell–intrinsic mechanism that limits the 
production of IL-2 to promote Th17 differentiation.
miR-21 was one the earliest identified “oncomirs,” and there-
fore much of the research involving this miRNA has focused on 
its role in tumor promotion (66); however, our data build upon 
emerging reports establishing a crucial role for miR-21 in Th17-
mediated autoimmunity. Specifically, our study corroborates 
the previous observation that miR-21 is overexpressed in the 
CNS-infiltrating T cells of animals with EAE (67) and is consistent 
with miR-21 involvement in other autoimmune disease models. 
For example, silencing miR-21 in vivo has led to a significant reduc-
tion of splenomegaly in lupus mice (68), targeted ablation of miR-
21 has led to reduced lung eosinophilia after allergen challenge in 
mice (69), and most recently, Mir21–/– mice have been shown to be 
resistant to dextran sulfate sodium–induced (DSS-induced) coli-
tis (70). Supporting these animal models, increased expression 
inhibitor developed EAE. However, anti–miR-21 treatment sup-
pressed EAE induced by adoptive transfer of T cells differentiated 
under Th17-polarizing conditions (Figure 5D). We and others have 
demonstrated the therapeutic efficacy of LNA-modified oligonu-
cleotide (LNA–anti-miR-21) in EAE and other disease models (53–
55). We therefore investigated whether systemic administration 
of anti–miR-21 in vivo affects the course of EAE. Administration 
of LNA-modified anti–miR-21 during the preclinical stage of EAE 
(beginning on day 5 after immunization) substantially ameliorated 
clinical disease (Figure 5E). To investigate whether anti–miR-21 
treatment affected Ag-specific IL-17 recall responses, we isolated 
spleens from MOG-immunized mice treated with scrambled con-
trol or anti–miR-21 and stimulated them in vitro with MOG pep-
tide. We found that splenocytes from anti–miR-21–treated mice 
had diminished MOG-specific IL-17 expression (Figure 5F). In 
addition, consistent with our data and with the inhibitory effect of 
anti–miR-21 on clinical EAE symptoms, we found that anti–miR-21 
treatment prevented upregulation of Il17 transcripts in CD4+ T cells 
isolated from the CNS of anti–miR-21–treated mice (Figure 5G).
Discussion
Th17 cells play an important role in inflammation and autoim-
munity. Although the differentiation of Th17 cells is known to 
be regulated by specific transcription factors and cytokines, the 
role of miRNA pathways that intrinsically control Th17 differ-
entiation remains elusive. Here, we report that miR-21 expres-
sion is specifically elevated in Th17 cells. CD4+ T cells lacking 
miR-21 exhibit a specific Th17 cell defect in vitro and during 
neuroinflammatory disease in vivo. Resistance to EAE induc-
tion in Mir21–/– mice and the substantial reduction of IL-17+ CNS 
cell infiltrates in these mice demonstrate that miR-21 is crucial 
for the control of Th17 development. Critically, we found that 
in vivo silencing of miR-21 using LNA-modified anti–miR-21 
reduced the clinical severity of EAE and was associated with a 
decrease in Th17 cells.
TGF-β signaling plays an essential role in the generation of 
Th17 cells (6–8), yet little is known about the miRNA pathways 
that intrinsically control these pathways. Our results suggest that 
miR-21 promotes Th17 differentiation by targeting SMAD-7, a 
negative regulator of TGF-β signaling. SMAD-7 inhibits TGF-β–
induced transcriptional responses by blocking activation of 
SMAD-2/3 and their complex formation with SMAD-4 (18). Most 
importantly, SMAD-7 has been shown to bind to SMAD-2 and 
SMAD-3, which are thought to competitively bind to TGF-βRI, 
and prevents their activation upon TGF-β stimulation. Mecha-
nistically, we have shown that miR-21 deficiency renders T cells 
less sensitive to TGF-β–induced SMAD-2/3 activation due to 
enhanced SMAD-7. Overexpression of miR-21 reduced SMAD-
7 expression while upregulating SMAD-2/3 levels, and miR-21 
knockdown reversed this TGF-β–induced SMAD-7 expression. 
Furthermore, silencing SMAD-7 resulted in enhanced IL-17 pro-
duction, which correlated with increased SMAD-2/3 activation 
in T cells. Consistent with our data, a recent study demonstrated 
that the generation of Th17 cells is associated with increased 
TGF-β–induced SMAD-2/3 activation (21). As a functional 
miR-21 target, SMAD-7 therefore represents a distinct regulator 
of Th17 differentiation.
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Proliferation assay. CellTrace Violet–labeled naive CD4+ T cells 
were cultured in flat-bottom 96-well plates and stimulated with plate-
bound anti-CD3 (2 μg/ml) and anti-CD28 (2 μg/ml). Cell prolifera-
tion was assessed by flow cytometry after 72 hours of culture using 
the Proliferation Platform analysis tool in FlowJo (version 9) soft-
ware. We examined the following parameters, as defined by FlowJo 
software: Percent Divided, the fraction of original cell populations 
that have undergone at least 1 cell division; Division Index, average 
number of cell divisions that cells in the original cell population have 
undergone (includes undivided cells/peak); Proliferation Index, total 
number of cell divisions divided by the number of proliferating cells 
(excludes undivided cells/peak); Expansion Index, the fold-change 
expansion of the overall cultures (includes undivided cells/peak); 
and Replication Index, the fold-change expansion of only the prolif-
erating cells (excludes undivided cells/peak). Alternatively, spleno-
cyte suspensions were generated from MOG35–55-immunized WT and 
Mir21–/– mice. Splenocytes from individual mice depleted of rbc were 
labeled with CellTrace Violet and plated (5 × 105 cells/well) in 200 
μl Iscove’s modified Dulbecco’s medium (IMDM) with and without 
25 μg/ml MOG35–55 peptide. After 72 hours, proliferation of MOG35–55-
specific T cells was analyzed by flow cytometry.
IL-17 secretion assay. IL-17–secreting CD4+ T cells were isolated 
using the Miltenyi Biotec Mouse IL-17 Secretion Assay – Cell Enrich-
ment and Detection Kit. In brief, total CD4+ T cells from MOG35–55 
peptide–immunized WT mice were stimulated with PMA plus iono-
mycin for 4 hours. Subsequently, an IL-17–specific catch reagent was 
attached to the cell surface of T cells. The cells were then incubated 
for 45 minutes at 37°C to allow cytokine secretion. The secreted IL-17 
binds to the IL-17 catch reagent on the positive IL-17–secreting cells. 
These cells were subsequently labeled with a second IL-17–specific 
detection antibody, and IL-17+ and IL-17–CD4+ T cells were sorted by 
flow cytometry.
Analysis of miR-21 expression. For analysis of miR-21 expression, 
real-time reverse transcription PCR (RT-PCR) was performed using 
TaqMan MicroRNA Assays (Applied Biosystems, Thermo Fisher Sci-
entific). Relative expression was calculated using the Ct method and 
of miR-21 has been observed in peripheral blood mononuclear 
cells from patients with MS (27). Increased miR-21 levels have 
also been reported in T cells from patients with SLE and psoriasis 
(28–30), and these levels correlated with disease activity. Given 
the ameliorating effect of anti–miR-21 we observed in EAE, the 
implication of miR-21 in multiple autoimmune disease models, 
and the expression profile of miR-21 in patients with MS and other 
autoimmune diseases, silencing miR-21 may be an effective thera-
peutic approach in the treatment of MS and other Th17-mediated 
inflammatory diseases. In conclusion, we have identified a T cell–
intrinsic miRNA pathway that enhances TGF-β signaling, limits 
the autocrine inhibitory effects of IL-2, and thereby promotes 
Th17 differentiation and autoimmunity.
Methods
Mice. C57BL/6, C57BL/6XSV129 (F1), Smad7fl/fl, and Cd4-Cre mice 
were obtained from The Jackson Laboratory. Mir21–/– C57BL/6xSV129 
(F1) mice were provided by Eric N. Olson (University of Texas South-
western Medical Center, Dallas, Texas, USA).
Induction and evaluation of EAE. Mice were injected s.c. into both 
flanks with 100 μg MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) 
dissolved in PBS emulsified in an equal volume of CFA (Difco) supple-
mented with 5 mg/ml Mycobacterium tuberculosis H37Ra. They were 
also injected twice i.p. with 200 ng PT (List Biological Laboratories) 
administered on the day of immunization and 48 hours later. Clinical 
assessment of EAE was performed daily after disease induction accord-
ing to the following criteria: 0, no disease; 1, tail paralysis; 2, hind limb 
weakness or partial paralysis; 3, complete hind limb paralysis; 4, fore-
limb and hind limb paralysis; 5, moribund state. Mean clinical scores on 
separate days were calculated by adding the scores of individual mice 
and dividing by the total number of mice in each group, including mice 
that did not develop signs of EAE. For histopathological studies, spinal 
cords were dissected from female mice (n = 5/group), fixed in 10% for-
malin in PBS, and embedded in a single paraffin block. Sections (6–10 
μm thick) were stained with H&E and Luxol fast blue. Stained sections 
were evaluated for immune cell infiltration and demyelination.
Figure 6. Model of molecular mecha-
nisms involved in miR-21 regulation of 
Th17 differentiation. Our study demon-
strates that miR-21 is increased in T cells 
stimulated under Th17-polarizing (TGF-β 
and IL-6) conditions. miR-21, in turn, pro-
motes TGF-β signaling by targeting the 
inhibitory SMAD SMAD-7. The enhanced 
TGF-β signaling in WT T cells suppresses 
IL-2 expression and promotes their dif-
ferentiation toward the Th17 phenotype. 
In the absence of miR-21, SMAD-7 levels 
are elevated, which in turn results in 
impaired TGF-β signaling, increased IL-2 
expression, and the observed inhibition 
of Th17 differentiation. Black arrows 
indicate conventional TGF-β signaling in 
Th17 differentiation. Blue arrows indicate 
the modulation of TGF-β signaling in 
Th17 differentiation in the presence or 
absence of miR-21. Proposed pathways 
are shown in WT (Mir21+/+) and miR-21–
deficient (Mir21–/–) T cells.
Downloaded from http://www.jci.org on February  9, 2015.   http://dx.doi.org/10.1172/JCI74347
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
1 0 jci.org
Cells were centrifuged at 900 g for 30 minutes at room temperature and 
incubated overnight. Cells were then centrifuged to remove the viral par-
ticles and cultured in fresh T cell differentiation medium. After 4 days, 
cells were analyzed for IL-17 expression by flow cytometry.
CD4+ T cell transfer. CD4+ T cells were prepared from the spleens 
and inguinal LNs of WT and Mir21–/– mice using the CD4+ T Cell Iso-
lation Kit (Miltenyi Biotec) (purity was >95%). CD4+ T cells (2 × 107 
cells/mouse) were injected i.v. into WT or Mir21–/– mice. Five days 
later, the recipient mice were subjected to EAE induction. For Th1- 
and Th17-mediated EAE, WT and Mir21–/– mice were immunized with 
MOG35–55 peptide emulsified in CFA. Ten days after immunization, 
mice were sacrificed, and CD4+ T cells from spleens and inguinal LNs 
were cultured for 5 days in the presence of 50 μg/ml MOG peptide 
and 20 ng/ml IL-23 to generate Th17 cells, or with MOG peptide and 
20 ng/ml IL-12 to generate Th1 cells. Naive 2D2 CD4+ T cell–polarized 
Th17 cells in the presence or absence of miR-21 inhibitors (2 × 107 
cells per mouse) were transferred into naive mice. Transplanted mice 
were injected with PT on the day of T cell transfer and again 48 hours 
later. EAE progression was monitored as described above.
Preparation and evaluation of CNS cells. Animals were perfused 
with cold PBS. Brains and spinal cords were dissected and incubated 
in 2.5 mg/ml collagenase D for 30 minutes at 37°C. Single-cell suspen-
sions were prepared by passing them through a 70-μm strainer. Cells 
were washed in RPMI 1640 medium, and mononuclear cells were iso-
lated using a discontinuous Percoll gradient (Pharmacia). Cells were 
washed twice, and CD4+ T cells were isolated from this suspension by 
magnetic separation using microbeads (Miltenyi Biotec).
Luciferase assay. Semiconfluent (70%–80%) HEK-293 cells were 
cotransfected with pRL-GAPDH (gift of Matthias Brock, Center of 
Experimental Rheumatology, University Hospital Zurich, Switzer-
land) and SMAD-7 WT or mutant luciferase constructs using Dhar-
maFECT Duo Transfection Reagent (GE Healthcare) according to the 
manufacturer’s instructions, washed 6 hours after transfection, and 
incubated for 24 hours. Cells were then lysed by passive lysis buffer, 
and luminescence was measured using the Dual-Glo Luciferase Assay 
System (Promega) on a Veritas Luminometer (Turner BioSystems). 
SMAD-7 luciferase readings (firefly luciferase) were normalized to 
GAPDH luciferase (Renilla luciferase) readings, and fold changes 
were calculated as compared with those in control cells.
MOG tetramer staining. Splenocytes derived from WT and Mir21–/– 
mice immunized with MOG35–55 peptide were harvested at disease onset 
and stained with MOG38–49-PE tetramer (1:100) or control tetramer–PE 
(NIH Tetramer Facility) for 2 hours at room temperature in IMDM and 
analyzed by flow cytometry.
Immunoblotting. Naive CD4+ T cells were stimulated for 24 hours 
with plate-bound anti-CD3 and anti-CD28. After a 16-hour resting 
period, cells were stimulated with TGF-β (2 ng/ml) at the indicated 
time points (Figure 4, A and B). Cells were homogenized in RIPA 
buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40), 1X pro-
tease inhibitor cocktail (Roche Applied Science), and 1X phosphatase 
inhibitor cocktail (Sigma-Aldrich), and equal amounts of protein 
(25 μg) were resolved by polyacrylamide gel electrophoresis. Pro-
teins were transferred onto a nitrocellulose membrane, and immu-
noblotting was performed with mouse monoclonal anti–SMAD-7 
(R&D Systems), GAPDH and α-tubulin (Sigma-Aldrich), rabbit poly-
clonal p–SMAD-2, p–SMAD-2, SMAD-3, p-p38MAPK, p-ERK, p-JNK, 
p38MAPK, ERK, and JNK antibodies (Cell Signaling Technology). 
normalized to uniformly expressed U6 snRNA or snoRNA135 (Applied 
Biosystems, Thermo Fisher Scientific). miR-21 values were expressed 
relative to the expression of U6 snRNA or snoRNA135. The levels of 
miR-21 in CNS-infiltrating T cells during peak EAE were normalized 
to T cells isolated from spleens of naive mice.
RNA isolation, cDNA synthesis, and real-time RT-PCR. Total RNA was 
isolated from cell pellets using the RNeasy Micro Kit (QIAGEN). RNA 
was stored at –80°C. First-strand cDNA synthesis was performed for each 
RNA sample from 0.5 to 1 μg of total RNA using TaqMan reverse tran-
scription reagents. cDNA was amplified using sequence-specific prim-
ers. The probes used were identified by the following Applied Biosystems 
assay numbers: Ifng, Mm01168134_m1; Il17a, Mm99999062_m1; Rorgt, 
Mm01261019-m1; Rora, Mm00443103_m1; Irf4, Mm00516431_m1; 
Batf, Mm00479410_m1; Hif1a, Mm01283760_m1; Il17f, Mm00521423_
m1; Foxp3, Mm00475151_m1; Il4, Mm00445259_m1; Il23r, 
Mm00519942_m1; Il23, Mm01160011_m1; Il6, Mm99999064_m1; 
Il1b, Mm01336189_m1; Tnfa, Mm00443258_m1; Ccr6, Mm01323931_
m1; Il6r, Mm00439653_m1; Tgfbr1, Mm00436964_m1; Tgfbr2, 
Mm00436977_m1; Il2, Mm00434256_m1; Btg2, Mm00476162_m1; 
Pdcd4, Mm01266062_m1; Pten, Mm00477208_m1; Spry1, 
Mm01285700_m1; Spry2, Mm00442344_m1; and Real-Time PCR Mix 
(Applied Biosystems, Thermo Fisher Scientific) on the ABI7500 cycler. 
The Gapdh gene was used as an endogenous control to normalize for 
differences in the amount of total RNA in each sample. All values were 
expressed relative to Gapdh expression.
Anti–miR-21 treatment. An antisense oligonucleotide modified by 
LNA was synthesized to inhibit miR-21 (Exiqon). For in vivo anti–miR-
21 treatment, anti–miR-21 and scrambled controls (30 μg/mouse) 
were administered i.v. to MOG-immunized mice on days 5, 7, 9, 11, and 
13 after immunization.
Th differentiation. For in vitro Th17 cell differentiation, naive 
CD4+CD62LhiCD44lo T cells from WT and Mir21–/– mice were sorted 
by flow cytometry and activated with plate-bound anti-CD3 (2 μg/ml) 
and anti-CD28 (2 μg/ml) in the presence of TGF-β (2 ng/ml) and 
IL-6 (30 ng/ml). IL-2 activity in Th17 cell cultures was blocked with 
a combination of neutralizing anti–IL-2 (10 μg/ml) and blocking 
anti–CD25 (10 μg/ml) antibodies (BD Biosciences). For Th1 polar-
izations, naive CD4+ T cells were activated with IL-12 (20 ng/ml) 
in the presence of anti–IL-4 (20 μg/ml) antibody (BD Biosciences). 
For Th2 polarizations, naive CD4+ T cells were activated with IL-4 
(20 ng/ml) in the presence of anti–IFN-γ (20 μg/ml) antibody (BD 
Biosciences). For iTreg differentiations, naive CD4+ T cells were 
activated with TGF-β (5 ng/ml) in the presence of IL-2 (50 U/ml). 
Twenty-four hours after culture, transcription factor expression was 
analyzed by real-time RT-PCR. Five days after activation, cells were 
restimulated with PMA plus ionomycin for 4 hours for intracellular 
cytokine analysis by flow cytometry.
Generation and isolation of DCs. DCs were derived from BM pro-
genitor cells. In brief, femoral and tibial cells were harvested in DC 
culture medium (RPMI 1640 medium, 10% FCS, 100 U/ml penicillin, 
100 μg/ml streptomycin, 20 ng/ml GM-CSF, and 10 ng/ml IL-4) and 
seeded in 24-well plates at a density of 1 × 106 cells/ml/well. Culture 
medium was replaced with fresh medium after 3 days. On day 6, dis-
lodged cells were used as BM-derived DCs. Splenic DCs were isolated 
from spleens using magnetic CD11c beads (Miltenyi Biotec).
Lentiviral shRNA transfection. CD4+ T cells were cultured in the pres-
ence of lentiviral particles and polybrene (8 μg/ml) (Sigma-Aldrich). 
Downloaded from http://www.jci.org on February  9, 2015.   http://dx.doi.org/10.1172/JCI74347
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
1 1jci.org
pRL-GAPDH, and G. Liu (University of Alabama at Birmingham, 
Birmingham, Alabama, USA) for the SMAD-7 WT and mutant 
luciferase constructs. This work was supported by grants from the 
NIH (AI435801 and NS38037, to H.L. Weiner); the Nancy Davis 
Foundation for MS (to G. Murugaiyan); the National Multiple Scle-
rosis Society (RG 4904A2/1, to G. Murugaiyan); and the Swiss 
National Science Foundation (PP00P3_150663, to N. Joller). The 
Vaidya laboratory is supported by an NIH Outstanding New Envi-
ronmental Scientist Award (ES017543).
Address correspondence to: Gopal Murugaiyan or Howard L. 
Weiner, Ann Romney Center for Neurologic Diseases, Brigham 
and Women’s Hospital and Harvard Medical School, HIM 720, 
77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA. 
Phone: 617.849.0912; E-mail: mgopal@rics.bwh.harvard.edu (G. 
Murugaiyan). Phone: 617.525.5300; E-mail: hweiner@rics.bwh.
harvard.edu (H.L. Weiner).
SMAD-7 HRP–conjugated secondary antibodies against mouse or 
rabbit were purchased from Jackson ImmunoResearch. Images were 
captured using the Bio-Rad ChemiDoc MP imaging system.
Statistics. Statistical analysis was performed using the unpaired 
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Supplemental Figure 1. Signature gene expression in in vitro differentiated 
Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4+ T cells were cultured 
under Th0, Th1, Th2, Th17, and Treg conditions. mRNA levels of specific 
transcription factors and cytokines were analyzed by quantitative RT-PCR. (B) 
Quantitative RT-PCR analysis of Mir-21 expression in naïve CD4+ T cells 
activated with plate bound anti-CD3 (2 µg/ml) and anti-CD28 (2 µg/ml) in the 
presence or absence of Th17-polarizing conditions. (C) CCR6+ and CCR6- 
populations were sorted from the in vitro differentiated Th17 culture and 
expression of IL17 was assessed by quantitative RT-PCR. (D) IL-17+ and IL-17- 
populations were sorted using a mouse IL-17 secretion assay and expression of 
IL17 was assessed by quantitative RT-PCR. Data are from two independent 
experiments. Error bars, mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, unpaired 
Student’s t test. 	  	  
	   2	  
 
 
Supplemental Figure 2. Mir-21 deficiency does not affect Th1, Th2, and Treg 
cells. (A) WT and Mir-21-/- derived naïve CD4+ T cells cultured under Th1 and 
Th2 conditions were restimulated with PMA/ionomycin on day 5 and stained for 
IL-4 and IFN-γ. Numbers represent the frequency of CD4+ T cells.   (B) WT and 
Mir-21-/--derived naïve CD4+ T cells cultured under iTreg conditions were stained 
for Foxp3. Numbers represent the frequency of CD4+ T cells. (C) Representative 
FACS plots display CD25+ Foxp3+ natural Treg  (nTreg) cells in the thymus and 
spleen. Numbers represent the frequency of CD4+ T cells. Data are 
representative of three independent experiments. 
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Supplemental Figure 3. Mir-21 deficiency does not cause any apparent 
global immune abnormalities in terms of myeloid and lymphoid cell 
subsets (A) Frequency of CD4 and CD8 double positive and CD4 and CD8 
single positive T cells from thymus, spleen, and LN  (B-D) Frequency of B220+ 
CD19+ B cells, CD11c+MHC-II+ DCs, and NK1.1+CD49b+ NK cells in spleen (E) 
Total cellularity of spleen and LN from 6-8 week-old WT and Mir-21-/- mice. (F) 
Gross morphology of spleens and LN. Data are representative of two 
independent experiments. 
	   4	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Supplemental Figure 4. Mir-21 deficiency does not affect antigen specific 
expansion of T cells. (A). Real-time PCR analysis of Mir-21 targets btg2, pten, 
pdcd-4, spry1, and spry2 in WT and Mir-21-/- T cells stimulated with plate-bound 
anti-CD3 and anti-CD28 antibodies (2µg/ml). (B) Real-time PCR analysis of Mir-
21 targets btg2, pten, pdcd-4, spry1, and spry2 in CD4+ T cells isolated from 
MOG35-55 immunized WT and Mir-21-/- mice. (C) Naïve CD4+ T cells from WT and 
Mir-21-/- mice were labeled with CellTrace Violet and stimulated in the presence 
of plate bound anti-CD3 and anti-CD28 antibodies (2µg/ml) for 72 hours. 
Proliferating T cells were analyzed by flow cytometry. (D) Splenocytes from 
MOG-immunized WT and Mir-21-/- mice were labeled with CellTrace Violet and 
stimulated in the presence or absence of MOG35-55 peptide (25 µg/ml) for 72 
hours. Proliferating CD4+ T cells from both groups were analyzed by flow 
cytometry. (E) The percentage of annexin V+ and 7-amino-actinomycin D+  
(7AAD+)  CD4+ T cells are shown (F) Frequencies of annexin V+ and annexin V+ 
7-amino-actinomycin D+  (7AAD+) CD4+ T cells from spleen and LN of MOG35-55 -
immunized WT and Mir-21-/- mice (n=3). (G) Total cellularity of splenocytes and 
CD4+ cells in MOG35-55-immunized WT and Mir-21-/- mice (n=3). (H) Frequency of 
activated CD4+ T cells from spleen and LN of MOG35-55-immunized WT and Mir-
21-/- mice (n=3). (I) Frequency of MOG tetramer+ T cells from spleen of MOG35-55-
immunized WT and Mir-21-/- mice (n=3). Data are representative of three 
independent experiments. Error bars, mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, unpaired Student’s t test. 
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Supplemental Figure 5. Defective Th17 cytokine expression in CNS 
infiltrating T cells from Mir-21-/- mice. FACS analysis of IL-17A, IL-17F, IL-21, 
and IL-22 expression in CNS-infiltrating T cells from WT and Mir-21-/- mice with 
peak EAE (n=3). Numbers represent the frequency of CD4+ T cells.  Data are 
representative of three independent experiments. 	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Supplemental Figure 6. Diminished frequencies and absolute numbers of 
Th17 cells in Mir-21-/- mice with EAE. IL-17 production by CNS-infiltrating CD4+ 
T cells from WT and Mir-21-/- mice with onset and peak EAE (n=3). CNS 
infiltrating CD4+ T cells were stimulated for 4 hr with PMA plus ionomycin in the 
presence of Golgi stop and analyzed for IL-17 expression. Data are 
representative of two independent experiments. Error bars, mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001, unpaired Student’s t test. 
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Supplemental Figure 7. Diminished frequencies of Th17 cells in the 
periphery of Mir-21-/- mice with EAE. FACS analysis of frequencies of IL-17 
producing CD4+ T cells from spleen and LN of WT and Mir-21-/- mice with onset 
and peak EAE. Spleen and LN cells were stimulated for 4 hr with PMA plus 
ionomycin in the presence of Golgi stop and analyzed for IL-17 expression. Data 
are representative of two independent experiments. 
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Supplemental Figure 8. Mir-21-/- dendritic cells (DCs) display an unimpaired 
phenotype. (A) The DC markers CD40, CD80, CD86, and MHC-II are 
appropriately expressed on the surface of Mir-21-/- DCs compared to WT DCs. 
DCs were stained for CD11C, MHCII, CD40, CD80, and CD86 and analyzed by 
flow cytometry. Histograms represent frequency of CD11c+ cells. (B) LPS-
stimulated Mir-21-/- DCs express normal levels of the Th17-polarizing cytokines 
IL-1β, IL-6, IL-23, and TNF-α. The data are representative of two independent 
experiments. (C) CD4+ T cells isolated from WT and Mir-21-/- mice were co-
cultured with CD11c+ DCs derived from WT and Mir-21-/- mice for 5 days and IL-
17 expression in CD4+ T cells was analyzed by flow cytometry. Numbers 
represent frequency of CD4+ T cells. Data are from two independent 
experiments. 	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Supplemental Figure 9. Unaltered innate lymphoid cells (ILCs) in Mir-21-/- 
mice. (A) Flow cytometry analysis of innate lymphoid cells (ILCs) in spleen and 
LN of MOG35-55-immunized WT and Mir-21-/- mice. ILCs are defined as CD45+ 
Lin- (CD3-, Ly6C/G-, B220-, CD11b-, and CD11C-) CD127+ CD117+ cells. (B) 
Quantitative RT-PCR analysis of IL-17 expression in sorted CD127+ CD117+ 
ILCs from WT and Mir-21-/- mice. Data are from two independent experiments. 
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Supplemental Figure 10. Mir-21-/- Th1 cells fail to induce EAE. WT and Mir-
21-/- mice were immunized with MOG35-55 peptide emulsified in CFA. At 10 days 
post MOG immunization, mice were sacrificed and CD4+ T cells from spleen and 
LN were cultured for 5 days with MOG peptide (50 µg/ml) in the presence of IL-
12 (20 ng/ml) before injection into WT recipients (2x107 cells/mouse). Recipients 
were injected with PT on the day of T cell transfer and again two days later. 
Clinical signs of EAE were monitored daily. Data are representative of two 
independent experiments. 
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Supplemental Figure 11. Unaltered IL-6R and IL-6-induced STAT3 
phosphorylation in Mir-21-/- CD4+ T cells. (A) Flow cytometry analysis of IL-6- 
induced STAT3 phosphorylation in CD4+ T cells from WT and Mir-21-/- mice. (B) 
The mRNA expression of IL-6R was analyzed by quantitative RT-PCR. Data are 
from two independent experiments. Error bars, mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, unpaired Student’s t test. 
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Supplemental Figure 12. TGF-β  and TGF-βR expression is normal in Mir-21-
/- CD4+ T cells. Quantitative RT-PCR analysis of TGF-β and TGF-βR expression 
in naïve CD4+ T cells from WT and Mir-21-/- mice. Data are from two independent 
experiments. Error bars, mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, unpaired 
Student’s t test. 
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Supplemental Figure 13. TGF-β-induced non-Smad signaling pathway is 
normal in Mir-21-/- T cells. CD4+ T cells from WT and Mir-21-/- mice were 
stimulated for 24 hours with plate-bound anti-CD3 and anti-CD28 antibodies 
(2µg/ml). After 12 hours of resting, cells were stimulated with TGF-β (2 µg/mL) for 
the indicated times. Phosphorylated and total P38MAPK, ERK, and JNK proteins 
were detected in Western blot assays of cell lysates. Data are from two 
independent experiments. 
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